U.S. Office REITs Stock News

Settlement gives Atkore investors fresh context Atkore (ATKR) has agreed to a US$50 million settlement with the third putative class in the PVC Pipe Antitrust Litigation, subject to court approval. The agreement aims to resolve End User Plaintiff claims and reduce legal uncertainty. See our latest analysis for Atkore. Atkore’s US$79.27 share price follows a 41.2% 3 month share price return and a 23.03% year to date share price return, while the 3 year total shareholder return is down 40.98%...

How Walmart stock has been trading recently Walmart (WMT) has attracted fresh attention after a mixed stretch in the share price, with the stock up slightly in the past week but down over the past month and past 3 months. See our latest analysis for Walmart. That recent pullback, with a 30 day share price return of down 7.9% and a 90 day share price return of down 3.2%, sits against a much stronger backdrop. The year to date share price return is 7.3% and the 1 year total shareholder return...

RLJ Lodging Trust’s Board of Trustees has declared a past quarterly cash dividend of $0.15 per common share for the second quarter of 2026, payable on July 15, 2026, to shareholders of record as of June 30, 2026, alongside a $0.4875 Series A preferred dividend payable on July 31, 2026. These continued common and preferred dividend payments, coming after stronger earnings and debt refinancing progress, highlight management’s emphasis on returning cash to investors while maintaining capital...

In early June 2026, Instacart announced it had launched its AI-powered Caper Carts at select Weis Markets stores in Pennsylvania, with further rollouts planned this year to bring real-time spend tracking, personalized digital coupons, and on-cart loyalty integration to shoppers. This expansion also gives Weis a new retail media channel through on-cart advertising and location-aware prompts that can influence basket size and product discovery in-store. We’ll now examine how introducing...

Earlier this year, COMPASS Pathways reported that its lead therapy, COMP360, achieved statistically significant reductions in depressive symptoms in a Phase 3 program and advanced a rolling FDA New Drug Application, materially lowering regulatory uncertainty around its first potential product. This progress marks a shift from pure clinical research toward building a commercial-scale mental health platform, which could make COMPASS Pathways more interesting to larger pharmaceutical companies...

In recent days, Precigen announced that the FDA has granted orphan drug exclusivity to PAPZIMEOS for recurrent respiratory papillomatosis (RRP), following long‑term data showing durable responses in patients treated with this HPV‑targeted immunotherapy. The new exclusivity, combined with multi‑year response durability data presented at ASCO, strengthens PAPZIMEOS’s position as a potential standard of care in this rare disease. We’ll now examine how orphan drug exclusivity for PAPZIMEOS could...

In recent days U.S. Bancorp completed several senior unsecured, fixed-rate medium-term note offerings totaling roughly US$25.34 million, with coupons between 5.00% and 6.00% and maturities stretching from 2036 to 2046. These callable bond issues deepen the bank’s long-dated funding while aligning with management’s emphasis on fee-driven earnings, disciplined costs, and capital flexibility. Next, we’ll explore how this fresh long-term funding, combined with cost discipline, may influence U.S...

BGC Group (BGC) is back in focus after its leadership used recent Morgan Stanley and Piper Sandler conferences to spotlight a shift toward electronic trading platforms Fenics and FMX, alongside cost and capital return plans. See our latest analysis for BGC Group. The recent conferences and macro headlines appear to have increased interest in BGC, with a 1-day share price return of 5.7%, a 90-day share price return of 20.4%, and a 3-year total shareholder return above 150%, indicating momentum...

Multiple Wall Street firms recently turned more positive on Nucor (NUE), pointing to expected strong quarterly results, resilient steel pricing under Section 232 tariffs, and improving free cash flow and demand trends. See our latest analysis for Nucor. Nucor's recent analyst upgrades and record high share price have arrived alongside a strong run of momentum, with a 30 day share price return of 17.32% and a 1 year total shareholder return of 122.23%. The 3 year total shareholder return of...

On 10 June 2026, Alkami Technology, Inc. announced an integration with Yodlee to transition its data aggregation services to the Financial Data Exchange (FDX) API using OAuth 2.0, aiming to replace screen scraping with more secure, efficient data sharing for financial institutions on its platform. By being one of the few digital banking platforms offering direct, large-scale FDX API integrations as a built-in capability, Alkami is sharpening its differentiation in secure, standards-based...

Universal Display Corporation recently opened its OLED Technology and Innovation Center in Chengdu, China, adding laboratories and a dedicated customer support hub in one of the country’s key OLED manufacturing regions. The facility is intended to deepen collaboration with local panel makers by supporting materials characterization, device optimization and application development across the full OLED design and production cycle. Next, we’ll examine how this Chengdu R&D and customer support...

Earlier this month, Watts Water Technologies reported Q1 results that surpassed analyst expectations on revenue growth and profitability, aided by firm pricing, productivity gains under its One Watts system, and resilient demand across key end markets. The company’s emphasis on innovation, higher-growth opportunities, and recent acquisitions appears to be broadening its revenue base and strengthening its positioning in attractive water infrastructure segments. Next, we examine how strong Q1...

Kymera Therapeutics recently reported Phase 1 data from KT-621, its first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association meeting in Kyoto, showing rapid, sustained STAT6 degradation, robust biomarker effects and a favorable safety profile consistent with earlier studies. By aligning pharmacokinetic, pharmacodynamic and safety data in Japanese participants with prior global results, Kymera cleared an important regulatory step toward...

Recent commentary on Yum China Holdings (YUMC) points to ongoing pressure from weak same-store sales, limited pricing flexibility, and expectations for soft demand ahead. These factors appear to be shaping how investors view the stock. See our latest analysis for Yum China Holdings. The recent concerns around weak same-store sales and pricing power seem to be reflected in Yum China Holdings' share price, which is around $44.63, with the 90 day share price return down 17.35%, while the 1 year...

Recent performance snapshot Conagra Brands (CAG) has drawn investor interest after recent trading, with the stock last closing at $13.74. Short term returns are positive, while performance over the past 3 months and the past year reflects meaningful declines. See our latest analysis for Conagra Brands. Recent share price gains over the past week and month contrast with a much weaker picture over longer periods. The 1 year total shareholder return is down 30.88% and the 5 year total...

McEwen Inc. recently released a Pre-Feasibility Study for its 100%-owned Grey Fox gold project near Timmins, Ontario, outlining a planned 15‑year mine life, estimated initial capital spending of $181 million, and the use of existing Fox Complex processing infrastructure. The study outlines that Grey Fox could become the primary ore source for the Fox Complex from 2035, with management expecting life-of-mine EBITDA of around $902 million under its base-case gold price assumption. We’ll now...

Earlier in June 2026, Avista Corporation signed a non-binding memorandum of understanding with a Washington-based developer for a potential large-load electric service starting at 125 megawatts in 2029, with a possible path to 500 megawatts by 2032, subject to regulatory approvals and definitive agreements. Shortly afterward, Avista paused processing new large data center energy requests, highlighting how community concerns and regulatory coordination can meaningfully shape the pace and...

In recent months, Advance Auto Parts has continued its multi-year operational turnaround under CEO Shane O’Kelly, closing stores, exiting the Worldpac distribution business, and consolidating operations to address margin pressures and past overexpansion. An interesting angle is that investors appear increasingly focused on how this restructuring could unlock value relative to peers, especially given the company’s emphasis on tightening inventory discipline and refocusing on core...

Mortgage rate move puts focus on Federal Home Loan Mortgage stock Freddie Mac’s latest survey showed the average 30-year fixed mortgage rate at 6.52%, even as stronger employment trends helped existing home sales reach a five-month high and signaled renewed buyer confidence. That mix of higher borrowing costs and improving demand is front and center for investors watching Federal Home Loan Mortgage (FMCC), a core player in the US secondary mortgage market through its single-family and...

In recent weeks, Tsakos Energy Navigation has advanced its fleet renewal program with eco-friendly, dual-fuel vessels while insider share purchases have signaled management confidence amid ongoing industry and balance-sheet risks. This combination of greener fleet investment and insider buying is reshaping how investors weigh the company’s exposure to oil transport against its efforts to adapt to tighter environmental rules. We’ll now examine how the insider buying and eco-focused fleet...

Jazz Pharmaceuticals recently reported that the Phase 3 LAGOON trial of Zepzelca in relapsed second-line metastatic small cell lung cancer failed to improve overall survival versus physician’s choice of chemotherapy, although safety remained consistent with prior data. An important nuance is that these LAGOON results do not affect Zepzelca’s existing full U.S. approval in the first-line maintenance setting, leaving its current commercial use in that indication unchanged while raising...

Brixmor Property Group (BRX) is back on investors’ radar after recent trading activity, following a consistent stock move over the past month and prompting closer attention to how its open air shopping center portfolio is being valued. See our latest analysis for Brixmor Property Group. At a share price of $32.58, Brixmor’s recent momentum is clear, with an 11.42% 30 day share price return and a 25.50% year to date share price return supporting a 33.40% 1 year total shareholder return. This...

Structure Therapeutics announced that Phase 2b ACCESS trial results for its oral GLP-1 receptor agonist aleniglipron in people with overweight or obesity were published in Nature Medicine and presented at the American Diabetes Association’s 86th Scientific Sessions, showing statistically significant efficacy across three maintenance doses and a safety profile consistent with the GLP-1 class. The interim open-label extension data, indicating durable weight loss beyond 36 weeks and improved...

Peabody Energy’s Australian subsidiaries recently entered into new A$700,000,000 asset-backed surety bond facilities with Liberty Mutual and Swiss Re, replacing existing 100% cash-collateralised bonding programs and backed by substantially all of the obligors’ assets through 2031. By freeing up cash previously tied to reclamation guarantees and amending its revolving credit facility to support the new structure, Peabody is reshaping how it funds long-term mine rehabilitation obligations in...